Kenneth Freedberg, MD, MSc
Director of the Medical Practice Evaluation Center at Massachusetts General Hospital. Director of the Program in HIV Epidemiology and Outcomes Research in the Harvard University Center for AIDS Research (CFAR)
Contact: email@example.com (617) 724-8597
Dr Freedberg focuses on evaluating clinical outcomes and cost-effectiveness of care in the U.S. and globally. He has developed widely-used computer models of disease to incorporate epidemiologic, clinical, and cost data. The focus has been on HIV, TB, and other infectious as well as non-infectious chronic diseases. He has used these models to determine the cost and cost-effectiveness of different strategies for HIV care in the US as well as in countries in Europe, Africa, South America, and Asia. This research has informed clinical guidelines for HIV and other diseases. For the past 17 years, Dr. Freedberg has served as Program Director for the NIAID-sponsored T32 Program in AIDS Clinical Research Training. He has served as a mentor to over 20 post-doctoral trainees and four pre-doctoral trainees and currently mentors six post-doctoral trainees. Fifteen of these trainees have received federal funding, including K01, K23, K24, K25 and R01 awards. He received the Clifford A. Barger Mentoring Award at Harvard Medical School for his commitment to mentoring young investigators. Dr. Freedberg’s widely-recognized research in simulation modeling and cost-effectiveness analysis and his extensive track record of successful mentorship make him a valuable addition to this proposal. He collaborates with Drs. Rigotti and Bassett.
Optimizing HIV care in less developed countries
NIAID R01 AI058736 2003 – 18
This study assesses the clinical impact, cost, and cost effectiveness of alternative strategies for HIV management in South Africa, India, Côte d’Ivoire and Brazil.
Cost-effectiveness of preventing HIV complications
NIAID R01 AI042006 1998 – 2020
The goals of the project are to develop a computer simulation model of advanced HIV disease and to use that model to project the costs and consequences of alternative patient care strategies
HIV cure studies: risk, risk perception, and ethics
NIAID R01 AI114617 2015 – 19
The goal of this project is to assess the objective risks from HIV cure study participation, assess HIV investigators’ and HIV patients’ ethical evaluation and willingness to partake in such studies, and recommend ethical ways to conduct HIV cure studies
Calibration and simulation of the botswana combination prevention project
R01 MH104042 2015 – 18
Using mathematical modeling methods, this project will examine the impact of sexual networks on HIV transmission in Botswana
AIDS clinical trials group network (“ACTG”)
UO1 AI068636 2006 – 20
The goal of this project is to conduct cost-effectiveness studies alongside selected ACTG trials using the CEPAC model. Modeling studies will use efficacy and cost data from the clinical trials to project long-term clinical outcomes and costs, and to evaluate the cost-effectiveness of the clinical trial interventions
Pharmacogenomics of HIV therapy
NIH/NIAID R01 AI077505
07/01/15 – 06/30/20
The goal of this project is to model pharmacogenomics data in order to quantify the cost-effectiveness of human genetics testing to inform prescribing of medications used to treat HIV-1 infections.
Novel approaches to the design and evaluation of combination HIV prevention
NIMH R01 MH105203 2014 – 19
This study will use novel mathematical modeling methods to examine combination HIV prevention and new methods to examine the value of economic incentives to improve HIV outcomes including linkage, retention and adherence
Effectiveness of nurse-delivered care for adherence/mood in HIV in S. Africa
NIMH R01 MH103770 2015 – 20
This project is an effectiveness trial of cognitive behavioral therapy for adherence and depression, to be delivered by nurse interventionists in South Africa.
Rapid urine-based screening for tuberculosis to reduce AIDS-related mortality in hospitalized patients in Africa (STAMP) trial
Medical Research Council 2015- 18
The main aim of this work is to determine whether use of a fundamentally new approach to rapid diagnostic screening for HIV-associated TB using novel, high-sensitivity urine-based testing reduces all-cause mortality among HIV-infected patients admitted to medical wards in hospitals in southern Africa.